As the cult classic sci-fi monster movie turns 25, we look at why it eclipses everything Vin Diesel's antihero has done since ...

His son, Jack Kilmer, narrated the story by reading his father’s words. “I have behaved poorly, I have behaved bravely, I ...

Rivera went on to note that, with systems like the different Fuses and Solo/Duo play, there are "a lot of ways" to play the characters on the roster. Plus, this won't be a static game post-launch.

This would require greater innovation, incentives for scaling-up of bio-based solutions, and the removal of policy and infrastructure bottlenecks. Addressing the regional imbalance would also be ...

Adi has covered video games, biohacking, and more for The Verge since 2011. Chatbot service Character.AI is adding a new ‘Parental Insights’ feature, which lets teens send a weekly report of ...

The extensive data collection has enabled Character Bio to redefine the condition into genetically-defined subtypes, identify and prioritise potential therapeutic targets, and refine the subject ...

A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove of company-generated human data already in hand.

Boston-based Hill­star Bio on Tues­day be­came the lat­est im­munol­o­gy start­up launch, un­veil­ing a $67 mil­lion Se­ries A round ...

Character Biosciences, a biotechnology startup developing treatments for vision loss, said Tuesday it raised $93 million in a Series B round. The financing will help Character bring its two most ...

Hillstar Bio is revolutionizing autoimmune disease treatment through a precision-driven approach that selectively depletes pathogenic cells while preserving healthy ones. This method holds the promise ...

This advertisement has not loaded yet, but your article continues below. Five years after Harvey Weinstein was convicted of rape and taken to jail, he returns to court for a new trial covering the ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...